3 days Ago By ABMN Staff
Denali Therapeutics Inc. ( NASDAQ:DNLI – Free Report ) – Equities researchers at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued on Thursday, September 12th. Zacks Research analyst A.
Chakraborty now anticipates that the company will earn ($2.80) per share for the year, down from their prior forecast of ($2.79).
The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.54) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q4 2025 earnings at ($0.
65) EPS, Q1 2026 earnings at ($0.72) EPS, Q2 2026 earnings at ($0.75) EPS and FY2026 earnings at ($3.
01) EPS. Several other research analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $90.
00 target price on shares of Denali Therapeutics in a research report on Wednesday, September 4th. Citigroup upped their target price on Denali Therapeutics from $26.00 to $32.
00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $35.00 target price on shares of Denali Therapeutics in a research report on Monday, September 9th.
JPMorgan Chase & Co. upped their target price on Denali Therapeutics from $28.00 to $29.
00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Finally, Wedbush reduced their target price on Denali Therapeutics from $30.00 to $26.
00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.
33. Denali Therapeutics Price Performance Shares of NASDAQ DNLI opened at $30.77 on Monday.
The stock has a market capitalization of $4.41 billion, a P/E ratio of -32.05 and a beta of 1.
37. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $31.
00. The business has a fifty day moving average price of $23.87 and a 200 day moving average price of $21.
13. Denali Therapeutics ( NASDAQ:DNLI – Get Free Report ) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.
59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.09.
The company had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $10.00 million.
The company’s revenue for the quarter was down 99.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.
30 earnings per share. Insider Activity In other news, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction dated Monday, July 1st.
The stock was sold at an average price of $22.12, for a total value of $663,600.00.
Following the transaction, the director now directly owns 34,404 shares of the company’s stock, valued at $761,016.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website .
Corporate insiders own 7.90% of the company’s stock. Institutional Trading of Denali Therapeutics Several hedge funds and other institutional investors have recently bought and sold shares of DNLI.
Dana Investment Advisors Inc. lifted its stake in shares of Denali Therapeutics by 19.2% in the 2nd quarter.
Dana Investment Advisors Inc. now owns 34,269 shares of the company’s stock valued at $796,000 after purchasing an additional 5,513 shares during the period. Creative Planning raised its position in shares of Denali Therapeutics by 8.
7% in the second quarter. Creative Planning now owns 43,033 shares of the company’s stock worth $999,000 after acquiring an additional 3,458 shares during the period. Susquehanna Fundamental Investments LLC boosted its stake in shares of Denali Therapeutics by 5.
6% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 222,917 shares of the company’s stock worth $5,176,000 after acquiring an additional 11,900 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Denali Therapeutics by 15.
5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 172,281 shares of the company’s stock valued at $4,000,000 after acquiring an additional 23,165 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Denali Therapeutics by 58.
7% in the 2nd quarter. Millennium Management LLC now owns 619,929 shares of the company’s stock valued at $14,395,000 after purchasing an additional 229,313 shares in the last quarter. 92.
92% of the stock is owned by institutional investors and hedge funds. About Denali Therapeutics ( Get Free Report ) Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Read More Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
